Wednesday, September 28, 2016

Antacids


Class: Antacids and Adsorbents
ATC Class: A02A
VA Class: GA209
CAS Number: 53547-27-6
Brands: Alamag, Alamag Plus, Alka-Mints, Alka-Seltzer Gold Effervescent Antacid, Almacone, Almacone II Hi-Potency, ALternaGEL, Alu-Cap, Alu-Tab, Amphojel, Basaljel, Chooz, Citrocarbonate Granules, Di-Gel, Gaviscon, Gaviscon Extra Strength, Genaton, Kudrox, Lowsium, Lowsium Plus, Maalox, Maalox Advanced Regular Strength, Maalox Advanced Maximum Strength, Maalox Antacid/Anti-Gas Maximum Strength, Maalox Max Quick Dissolve Chewables Antacid/Antigas Maximum Strength, Maalox Quick Dissolve Chewables, Maalox Quick Dissolve Chewables Maximum Strength, Maalox TC, Mag-Al, Mag-Al Plus, Mag-Al XS, Mag-Ox, Marblen, Milk of Magnesia, Mygel, Mygel II, Mylanta, Mylanta Children’s Upset Stomach Relief, Mylanta Fast-Acting, Mylanta Fast-Acting Double Strength, Mylanta Fast-Acting Maximum Strength, Mylanta Supreme Fast Acting, Pepcid Complete, Phillips’ Milk of Magnesia, Riopan Plus, Riopan Plus Double Strength, Rolaids Antacid, Rulox, Tempo, Titralac Extra Strength, Titralac Plus, Titralac Regular, Tums Antacid/Calcium Supplement, Tums E-X Antacid/Calcium Supplement, Tums Ultra Antacid/Calcium Supplement, Uro-Mag

Introduction

Inorganic salts that partially neutralize gastric hydrochloric acid.b


Uses for Antacids


Peptic Ulcers


Adjunct to other drugs (e.g., anti-infectives, histamine H2-receptor antagonists, proton-pump inhibitors) for the relief of peptic ulcer pain and to promote the healing of peptic ulcers.b


Because of the inconvenience of the regimens needed to promote ulcer healing, high recurrence rate, ineffectiveness in eradicating Helicobacter pylori, palatability issues, and adverse effects, antacids rarely are used alone any longer for the treatment of peptic ulcer disease.200 220 234 238 242 243 252 b d Instead, antacids currently are used principally as an adjunct to other antiulcer regimens for as-needed (prn) relief of peptic ulcer pain.b d


Acid Indigestion


Self-medication for the relief of acid indigestion (dyspepsia), heartburn, and sour stomach and/or bloating (commonly referred as gas).267 a


Gastroesophageal Reflux Disease (GERD)


Self-medication for the relief of mild forms of GERD (e.g., symptoms induced by a heartburn-inducing meal).265 a e


Antacids generally provide more rapid but less prolonged relief of GERD symptoms compared with histamine H2-receptor antagonists, and combined therapy generally is more effective than either class of drugs alone.e


Consult a clinician if symptoms persist or warning signs of more severe GERD develop (e.g., dysphagia, bleeding, weight loss, choking [acid-induced cough, shortness of breath, and/or hoarseness], chest pain).265 e


Other agents (e.g., histamine H2-receptor antagonists, proton-pump inhibitors) preferred by American College of Gastroenterology (ACG) and American Gastroenterological Association (AGA) for management of more severe forms of GERD.265 b e


Have been used for self-medication for the relief of breakthrough symptoms in patients receiving proton-pump inhibitors.e


Hyperphosphatemia


Aluminum-containing antacids (except aluminum phosphate): Management of hyperphosphatemia or prevention of recurrent phosphatic renal calculi (in conjunction with a low phosphate diet).a b


Aluminum carbonate generally preferred to aluminum hydroxide for this use.b


Calcium Replacement


Calcium carbonate is used for calcium supplementation.b


Stress Ulceration and GI Bleeding


Has been used for prevention of stress ulceration and GI bleeding.b


Gastric Acid Aspiration


Has been used for prevention of gastric acid aspiration in patients undergoing cesarean section or emergency surgery;b generally has been replaced by histamine H2-receptor antagonist or citrate solution.c


Antacids Dosage and Administration


Administration


Oral Administration


Administer orally.b


Oral suspensions more rapidly and effectively solubilized than powders or tablets; reserve oral tablets for chronic use in patients who refuse oral suspensions because of inconvenience or unpalatable taste.b Rapidly disintegrating tablets may be a suitable alternative in some patients.b


Chew tablets, including rapidly dissolving tablets, thoroughly before swallowing.b


Dosage


Available as various inorganic salts (e.g., aluminum carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium oxide, sodium bicarbonate); dosage is expressed in terms of mEq of acid neutralizing capacity.b


Dose and frequency of administration depend on the acid secretory rate of the stomach, gastric emptying time, and the disorder being treated.b


Adults


Peptic Ulcers

For peptic ulcer disease, dosages of antacids are empirical and various antacid dosages have been used.b


Adjunctive Therapy

Oral

For supplemental ulcer pain relief, 40–80 mEq acid neutralizing capacity on an as-needed (prn) basis.f


Treatment

Oral

Other therapies currently are preferred for treatment of active peptic ulcers.200 220 234 238 242 243 252 b d (See Peptic Ulcers under Uses.)


If antacids are used for the treatment of peptic ulcers, usual high-dose regimens for ulcer healing employ 80–160 mEq acid neutralizing capacity, given 1 and 3 hours after meals and at bedtime.f


Additional doses of antacids may be administered to relieve ulcer pain that occurs between regularly scheduled doses.b


In patients with duodenal ulcers, antacids usually are given for 4–6 weeks.b If symptoms of duodenal ulcer recur, antacids can be administered 1 and 3 hours after meals and at bedtime for 1 week and, if pain is relieved, less frequently for an additional 1–2 weeks.b


In patients with gastric ulcers, antacids are administered until healing is complete.b


Gastroesophageal Reflux Disease (GERD)

For GERD, dosages of antacids are empirical and various antacid dosages have been used.b d f


Oral

For relief of heartburn, one recommended regimen employs 40–80 mEq acid neutralizing capacity on an as-needed (prn) basis intially.d f If necessary, dosage can be titrated to a regularly scheduled basis such as 40–80 mEq acid neutralizing capacity given after meals and at bedtime.d f


Hyperphosphatemia

Oral

In conjunction with dietary phosphate restriction in the management of hyperphosphatemia, 30–40 mL of aluminum hydroxide or aluminum carbonate suspension is administered 3 or 4 times daily.


Calcium Replacement

Oral

For calcium replacement dosage with calcium carbonate, see Dosage in Calcium Salts 40:12.


Stress Ulceration and GI Bleeding

Oral

In the management of stress ulceration and GI bleeding, antacids are usually administered every hour, and the antacid dosage should be titrated to maintain the nasogastric aspirate above pH 3.5.b


For severe symptoms, antacid suspensions may be diluted with water or milk and given by continuous intragastric infusion.b


Gastric Acid Aspiration

Oral

To reduce the risk of anesthesia-induced gastric acid aspiration, an antacid suspension has been given 30 minutes before anesthesia.


Prescribing Limits


Adults


GERD

Oral

Do not exceed 500–600 mEq acid neutralizing capacity daily or regularly scheduled (versus as-needed; prn) therapy for longer than 2 weeks continuously.d f


Sodium Bicarbonate

Maximum daily dosage of sodium or bicarbonate is 200 mEq in patients <60 years of age and 100 mEq in patients >60 years of age.b Contraindicated for prolonged therapy because it may cause metabolic alkalosis or sodium overload.b


Cautions for Antacids


Contraindications



  • Sodium bicarbonate is contraindicated and use of other sodium-containing antacids should be restricted in patients on low-sodium diets and in those with CHF, renal failure, edema, or cirrhosis.b



Warnings/Precautions


Warnings


Phenylketonuria

Some antacids may contain aspartame (e.g., NutraSweet), which is metabolized in the GI tract to phenylalanine following oral administration.b


Sensitivity Reactions


Tartrazine Sensitivity

Some antacid formulations contain the dye tartrazine (FD&C yellow No. 5), which may cause allergic-type reactions (bronchial asthma in susceptible individuals) in certain susceptible individuals (e.g., patients who are sensitive to aspirin).b


General Precautions


Aluminum Antacids

Risk of hypophosphatemia with prolonged administration or large doses, particularly in patients with inadequate dietary intake of phosphorus.b


Monitor serum phosphate concentrations at monthly or bimonthly intervals in patients on maintenance hemodialysis who are receiving chronic aluminum antacid therapy.b


Calcium Carbonate

May cause gastric hypersecretion and acid rebound.b


May cause the milk-alkali syndrome (characterized by hypercalcemia, metabolic alkalosis and, rarely, renal insufficiency).b


Monitor serum calcium concentrations weekly and whenever manifestations of hypercalcemia occur in patients receiving large doses of calcium carbonate.b


Magnesium Antacids

Commonly cause a laxative effect, and frequent administration of these antacids alone often cannot be tolerated; repeated doses cause diarrhea which may cause fluid and electrolyte imbalances.b


Sodium Bicarbonate

May cause metabolic alkalosis when given in large doses.b


Medication Errors

Serious medication errors have been reported to FDA in which consumers used Maalox Total Relief (bismuth subsalicylate) when they intended to use traditional Maalox liquid antacid products containing aluminum hydroxide, magnesium hydroxide, and simethicone (e.g., Maalox Advanced Regular Strength, Maalox Advanced Maximum Strength).266 267 268 Because of the potential for serious adverse effects associated with accidental use of bismuth subsalicylate (which is chemically related to aspirin), the manufacturer of Maalox Total Relief initially agreed to change the trade name of the product to one that did not include “Maalox”; however, the manufacturer instead discontinued the bismuth subsalicylate preparation in the summer of 2010.267 269


Specific Populations


Renal Impairment

Aluminum Antacids: Long-term administration in patients with renal failure or chronic renal failure may result in hyperaluminemia since small amounts of aluminum are absorbed from the GI tract and excretion of aluminum is decreased in patients with renal failure.b Aluminum accumulation in the CNS may be the cause of dialysis encephalopathy, while aluminum accumulation in the bones may result in or worsen dialysis osteomalacia.b


Calcium Carbonate: Patients with renal impairment or dehydration and electrolyte imbalance are predisposed to developing the milk-alkali syndrome.b Hypercalcemia risk in chronic hemodialysis patients.b


Magnesium Antacids: In patients with severe renal impairment, hypermagnesemia characterized by hypotension, nausea, vomiting, ECG changes, respiratory or mental depression, and coma.b Do not administer in patients with renal failure, and antacids containing more than 50 mEq of magnesium in the recommended daily dosage should be used cautiously and only under the supervision of a clinician who should monitor electrolytes in patients with renal disease.b


Sodium Bicarbonate: May cause metabolic alkalosis in patients with renal insufficiency.b


Common Adverse Effects


With prolonged administration, constipation (e.g., aluminum salts, calcium carbonate), diarrhea (e.g., magnesium salts), gastric distension/flatulence (e.g., sodium bicarbonate), and gastric hypersecretion/acid rebound (e.g., calcium carbonate).b


Interactions for Antacids


All antacids potentially may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs by changing GI transit time or by binding or chelating the drug.b In vitro studies indicate that magnesium hydroxide or trisilicate has the greatest potential for drug binding and aluminum hydroxide and calcium carbonate are intermediate.b


Specific Drugs and Food







































Drug



Interaction



Comments



Aspirin



Pharmacokinetic (increased absorption of buffered or enteric-coated aspirin or decreased blood salicylate concentrations) interactionsb



Chlordiazepoxide



Possible decreased chlordiazepoxide absorption with aluminum hydroxide and magnesium preparationsb



Diazepam



Possible increased diazepam absorption with aluminum hydroxideb



Digoxin



Possible decreased digoxin absorptionb



Space doses of the drugs as far apart as possibleb



Indomethacin



Possible decreased indomethacin absorptionb



Space doses of the drugs as far apart as possibleb



Iron salts



Possible decreased absorption of iron saltsb



Space doses of the drugs as far apart as possibleb



Isoniazid



Possible decreased isoniazid absorption with aluminum hydroxideb



Administer isoniazid at least 1 hour before aluminum-containing antacidsb



Milk or other calcium-containing foods



Possible milk-alkali syndrome with chronic administration of bicarbonate and milk or calciumb



Naproxen



Possible increased naproxen absorption with sodium bicarbonateb


Possible decreased naproxen absorption with magnesium oxide or aluminum hydroxideb



Pseudoephedrine



Possible increased pseudoephedrine absorption with aluminum hydroxideb



Tetracyclines



Possible decreased tetracycline absorptionb



Allow 1–2 hours to elapse between doses of antacids and tetracyclinesb


ActionsActions



  • Mechanism of action in the treatment of peptic ulcers is based on ability of antacids to react with hydrochloric acid and thus increase gastric pH.b




  • With usual doses, antacids generally do not increase and maintain gastric pH above 4–5.b




  • Antacids, in decreasing order of their ability to neutralize a given amount of acid, are calcium carbonate, sodium bicarbonate, magnesium salts, and aluminum salts.b




  • Aluminum-containing antacids (except aluminum phosphate) combine with dietary phosphate in the intestine forming insoluble, nonabsorbable aluminum phosphate which is excreted in the feces.b If phosphate intake is limited and renal function is normal, aluminum antacids (except aluminum phosphate) decrease phosphate absorption and hypophosphatemia and hypophosphaturia occur.b




  • Magnesium-containing antacids have a laxative action.b



Advice to Patients



  • Advise patients to consult a clinician if ulcer pain worsens or is not relieved after the first week of therapy.b




  • Importance of consulting a clinician if GERD symptoms persist or warning signs of more severe GERD develop (e.g., dysphagia, bleeding, weight loss, choking [acid-induced cough, shortness of breath, and/or hoarseness], chest pain).265 d




  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.b




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.b




  • Importance of informing patients of other important precautionary information.b (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


















Aluminum Carbonate, Basic

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Capsules



equivalent to dried aluminum hydroxide gel 608 mg or aluminum hydroxide 500 mg



Basaljel



Wyeth



Tablets



equivalent to dried aluminum hydroxide gel 608 mg or aluminum hydroxide 500 mg



Basaljel (scored)



Wyeth


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name






































Aluminum Hydroxide

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Capsules



475 mg



Alu-Cap



3M



Suspension



320 mg/5 mL*



Aluminum Hydroxide Suspension



Amphojel



Wyeth



600 mg/5 mL



ALternaGEL



J&J-Merck



Tablets



300 mg



Amphojel



Wyeth



Tablets, film-coated



600 mg



Alu-Tab



3M


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name



















































































Calcium Carbonate, Precipitated (Precipitated Chalk)

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Bulk



Powder*



Oral



Pieces, chewing gum



500 mg



Chooz



Insight



Suspension



400 mg/5 mL



Mylanta Children’s Upset Stomach Relief



J&J-Merck



1.25 g/5 mL*



Calcium Carbonate Suspension



Tablets



1.25 g*



Calcium Carbonate Tablets (scored)



Tablets, chewable



400 mg



Mylanta Children’s Upset Stomach Relief



J&J-Merck



420 mg



Titralac Regular



3M



500 mg



Tums Antacid/Calcium Supplement



GlaxoSmithKline



650 mg*



Calcium Carbonate Chewable Tablets



750 mg



Titralac Extra Strength



3M



Tums E-X Antacid/Calcium Supplement



GlaxoSmithKline



850 mg



Alka-Mints



Bayer



1 g



Tums Ultra Antacid/Calcium Supplement



GlaxoSmithKline



Tablets, chewable, rapidly disintegrating



600 mg



Maalox Quick Dissolve Chewables



Novartis



1 g



Maalox Quick Dissolve Chewables Maximum Strength



Novartis


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name













Dihydroxyaluminum Sodium Carbonate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Bulk



Powder*













Magaldrate (Aluminum Magnesium Hydroxide)

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Suspension



540 mg/5 mL



Lowsium



Rugby























Magaldrate Combinations

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Suspension



540 mg/5 mL with Simethicone 40 mg/5 mL



Lowsium Plus



Rugby



Riopan Plus



Wyeth



1080 mg/5 mL with Simethicone 40 mg/5mL



Riopan Plus Double Strength



Wyeth


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name













Magnesium Carbonate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Bulk



Powder*


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name






































Magnesium Hydroxide

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Bulk



Powder*



Oral



Suspension



400 mg/5 mL*



Milk of Magnesia



Phillips’ Milk of Magnesia



Bayer



800 mg/5 mL



Phillips’ Milk of Magnesia Concentrate



Bayer



1.2 g/5 mL*



Milk of Magnesia Concentrate



Roxane



Tablets



300 mg*



Phillips’ Milk of Magnesia



Bayer


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

































Magnesium Oxide

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Bulk



Powder*



Oral



Capsules



140 mg



Uro-Mag



Blaine



Tablets



400 mg*



Magnesium Oxide Tablets



Mag-Ox 400



Blaine



420 mg*



Magnesium Oxide Tablets


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name













Magnesium Trisilicate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Bulk



Powder*


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name




























Sodium Bicarbonate (Baking Soda)

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Bulk



Powder*



Oral



For solution



0.78 g/3.9 g



Citrocarbonate Granules



Lee



Tablets



325 mg*



Sodium Bicarbonate Tablets



650 mg*



Sodium Bicarbonate Tablets




























Aluminum Hydroxide and Magnesium Carbonate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Suspension



Aluminum Hydroxide 31.7 mg/5 mL and Magnesium Carbonate 119.3 mg/5 mL



Gaviscon Liquid



GlaxoSmithKline



Genaton Liquid



Teva



Aluminum Hydroxide 254 mg/5 mL and Magnesium Carbonate 237.5 mg/5 mL



Gaviscon Extra Strength



GlaxoSmithKline



Tablets, chewable



Aluminum Hydroxide 160 mg and Magnesium Carbonate 105 mg



Gaviscon Extra Strength



GlaxoSmithKline






































Aluminum Hydroxide and Magnesium Hydroxide

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Suspension



Aluminum Hydroxide 200 mg/5 mL and Magnesium Hydroxide 200 mg/5 mL



Mag-Al



Pharmaceutical Associates



Aluminum Hydroxide 225 mg/5 mL and Magnesium Hydroxide 200 mg/5 mL



Alamag



Teva, URL



Maalox



Novartis



Rulox



Rugby



Aluminum Hydroxide 600 mg/5 mL and Magnesium Hydroxide 300 mg/5 mL



Maalox TC



Novartis



Tablets, chewable



Aluminum Hydroxide 200 mg and Magnesium Hydroxide 200 mg



Rulox #1



Rugby





























































































Aluminum Hydroxide and Magnesium Hydroxide Combinations

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Suspension



Aluminum Hydroxide 200 mg/5 mL, Magnesium Hydroxide 200 mg/5 mL, and Simethicone 20 mg/5 mL



Almacone



Rugby



Di-Gel



Schering-Plough



Maalox Advanced Regular Strength



Novartis



Mag-Al Plus



Pharmaceutical Associates



Mygel



Sandoz



Mylanta Fast-Acting



J&J-Merck



Aluminum Hydroxide 225 mg/5 mL, Magnesium Hydroxide 200 mg/5 mL, and Simethicone 25 mg/5 mL



Alamag Plus



Teva



Aluminum Hydroxide 400 mg/5 mL, Magnesium Hydroxide 400 mg/5 mL, and Simethicone 40 mg/5 mL



Almacone II Hi-Potency



Rugby



Antacid Double Strength



Teva



Maalox Advanced Maximum Strength



Novartis



Mag-Al XS



Pharmaceutical Associates



Mygel II



Sandoz



Mylanta Fast-Acting Double Strength



J&J-Merck



Aluminum Hydroxide 500 mg/5 mL, Magnesium Hydroxide 450 mg/5 mL, and Simethicone 40 mg/5 mL



Kudrox



Schwarz



Maalox Antacid/Anti-Gas Maximum Strength



Novartis



Tablets, chewable



Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg



Almacone



Rugby



Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 25 mg



Tempo



Blairex


















Aluminum Hydroxide and Magnesium Trisilicate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, chewable



Aluminum Hydroxide 80 mg and Magnesium Trisilicate 20 mg



Gaviscon



GlaxoSmithKline



Genaton



Teva













Calcium Carbonate and Magnesium Carbonate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Suspension



Calcium Carbonate 520 mg/5 mL and Magnesium Carbonate 400 mg/5 mL



Marblen



Fleming

































Calcium Carbonate and Magnesium Hydroxide

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Suspension



Calcium Carbonate 400 mg/5 mL and Magnesium Hydroxide 135 mg/5 mL



Mylanta Supreme Fast Acting



J&J-Merck



Tablets



Calcium Carbonate 550 mg and Magnesium Hydroxide 125 mg



Mylanta Gelcaps



J&J-Merck



Tablets, chewable



Calcium Carbonate 350 mg and Magnesium Hydroxide 150 mg



Mylanta Fast-Acting



J&J-Merck



Calcium Carbonate 500 mg and Magnesium Hydroxide 110 mg



Rolaids Antacid



Pfizer



Calcium Carbonate 700 mg and Magnesium Hydroxide 300 mg



Mylanta Fast-Acting Maximum Strength



J&J-Merck


















Calcium Carbonate and Magnesium Hydroxide Combinations

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets



Calcium Carbonate 280 mg, Magnesium Hydroxide 128 mg, and Simethicone 20 mg



Di-Gel



Schering-Plough



Tablets, chewable



Calicum Carbonate 800 mg, Magnesium Hydroxide 165 mg, and Famotidine 10 mg



Pepcid Complete



J&J-Merck


















Other Calcium Carbonate Combinations

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets



420 mg with Simethicone 21 mg



Titralac Plus



3M



Tablets, chewable, rapidly disintegrating



1 g with Simethicone 60 mg



Maalox Max Quick Dissolve Chewables Antacid/Antigas Maximum Strength



Novartis













Potassium Bicarbonate and Sodium Bicarbonate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, for solution



Potassium Bicarbonate 312 mg and Sodium Bicarbonate 958 mg



Alka-Seltzer Gold Effervescent Antacid



Bayer


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Calcium Carbonate 1250MG/5ML Suspension (ROXANE): 500/$20.99 or 1500/$40.97


Mag-Ox 400 400MG Tablets (HEALTH CARE PRODUCTS): 120/$21.99 or 240/$35.97


Mag-Oxide 400MG Tablets (RISING PHARMACEUTICALS): 30/$12.99 or 90/$15.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions February 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References


Only references cited for selected revisions after 1984 are available electronically.



200. Ateshkadi A, Lam NP, Johnson CA. Helicobacter pylori and peptic ulcer disease. Clin Pharm. 1993; 12:34-48. [IDIS 307044] [PubMed 8428432]



201. Blaser MJ. Helicobacter pylori: its role in disease. Clin Infect Dis. 1992; 15:386-91. [IDIS 301064] [PubMed 1520782]



202. Marshall BJ. Treatment strategies for Helicobacter pylori infection. Gastroenterol Clin North Am. 1993; 22:183-98. [PubMed 8449566]



203. Bayerdörffer E, Mannes GA, Sommer A et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol Suppl. 1993; 196:19-25. [PubMed 8341987]



204. Unge P, Ekstrom P. Effects of combination therapy with omeprazole and an antibiotic on H. pylori and duodenal ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:17-8.



205. Hunt RH. Hp and pH: implications for the eradication of Helicobacter pylori. Scand J Gastroenterol Suppl. 1993; 196:12-6. [PubMed 8341986]



206. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl. 1993; 196:34-7. [PubMed 8341989]



207. Bell GD, Powell U. Eradication of Helicobacter pylori and its effect in peptic ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:7-11. [PubMed 8341990]



208. Farrell MK. Dr. Apley meets Helicobacter pylori. J Pediatr Gastroenterol Nutr. 1993; 16:118-9. [PubMed 8450375]



209. Nomura A, Stemmermann GN, Chyou PH et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132-6. [PubMed 1891021]



210. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127-31. [PubMed 1891020]



211. The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993; 341:1359-62. [PubMed 8098787]



212. Talley NJ, Zinsmeister AR, Weaver A et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst. 1991; 83:1734-9. [PubMed 1770552]



213. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302:1302-5. [PubMed 2059685]



214. Forman D. Helicobacter pylori infection: a novel risk factor in the etiology of gastric cancer. J Natl Cancer Inst. 1991; 83:1702-3. [PubMed 1770545]



215. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am. 1993; 22:89-104. [PubMed 8449573]



216. Correa P. Is gastric carcinoma an infectious disease? N Engl J Med. 1991; 325:1170-1.



217. Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? Hum Pathol. 1993; 24:569-70.



218. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer with eradication of Helicobacter pylori. Lancet. 1990; 335:1233-5. [IDIS 267578] [PubMed 1971318]



219. Hunt RH. pH and Hp—gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993; 88:481-3. [IDIS 313340] [PubMed 8470623]



220. Reviewers’ comments (personal observations) on Helicobacter pylori. Clarithromycin 8:12.12.



221. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994; 89(Suppl):S116-28.



222. Labenz J, Gyenes E, Rühl GH et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut. 1993; 34:1167-70. [IDIS 320468] [PubMed 8406147]



223. Anon. Drugs for treatment of peptic ulcer. Med Lett Drugs Ther. 1994; 36:65-7. [PubMed 7912812]



224. Freston JW. Emerging strategies for managing peptic ulcer disease. Scand J Gastroenterol Suppl. 1994; 201:49-54. [PubMed 8047824]



225. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol Suppl. 1994; 201:16-23. [PubMed 8047818]



226. Labenz J, Rühl GH, Bertrams J et al. Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994; 89:726-30. [IDIS 329264] [PubMed 8172146]



227. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994; 35:19-22. [IDIS 324883] [PubMed 8307443]



228. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65-9. [IDIS 332306] [PubMed 8007082]



229. Fennerty MB. Helicobacter pylori. Ann Intern Med. 1994; 154:721-7.



230. Adamek RJ, Wegener M, Labenz J et al. Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol. 1994; 89:39-42. [IDIS 324011] [PubMed 8273795]



231. Cotton P. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats. JAMA. 1994; 271:808-9. [PubMed 8114221]



232. Feldman M. The acid test. Making clinical sense of the consensus conference on Helicobacter pylori. JAMA. 1994; 272:70-1. [PubMed 8007084]



233. Markham A, McTavish D. Clarithromycin and omeprazole: as Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs. 1996; 51:161-78. [PubMed 8741237]



234. Soll AH. Medical treatment of peptic ulcer disease. JAMA. 1996; 275:622-9. [IDIS 361115] [PubMed 8594244]



235. Murray DM, DuPont HL, Cooperstock M et al. Evaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease associated with infection by Helicobacter pylori. Clin Infect Dis. 1992; 15(Suppl 1):S268-73.



236.

No comments:

Post a Comment